What is Lineage Cell Therapeutics's market cap?

Lineage Cell Therapeutics (LCTX) has a market capitalization of $291.7M and trades on AMEX.

Who are Lineage Cell Therapeutics's competitors?

Lineage Cell Therapeutics's key competitors include Regeneron Pharmaceuticals, Inc., AbbVie Inc., Sana Biotechnology, Inc., and others. These companies compete in similar markets and product categories.

Who does Lineage Cell Therapeutics partner with?

Lineage Cell Therapeutics's notable partners include F. Hoffman-La Roche Ltd., Genentech, Inc., William Demant Invest 2 Aps, and others.

What subsidiaries does Lineage Cell Therapeutics have?

Lineage Cell Therapeutics's subsidiaries include Cell Cure Neurosciences Ltd., Asterias Biotherapeutics Incorporated.

Where is Lineage Cell Therapeutics headquartered?

Lineage Cell Therapeutics is headquartered in United States of America and employs approximately 75 people. It has been publicly traded since 1992.

Lineage Cell Therapeutics

LCTX

Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on the development of novel cell replacement therapies for serious medical conditions.

Market cap

$291.68M+18.3%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$1.7MMiss by $1.9M EPS-$0.03Miss by $0.01

Read the full report

Next report

Aug 11, 2026 (In 3 weeks)

Revenue estimate$1.8M

EPS estimate-$0.03

Competitors

By market cap

AbbVie$449.45B+32.2%

Regeneron Pharmaceuticals$71.2B+16.1%

Sana Biotechnology$882.2M-6.4%

Ocugen, Inc.$463.8M+39.3%

Lineage Cell Therapeutics$291.7M+24.0%

Outlook Therapeutics, Inc.$216.9M+145%

Aldeyra Therapeutics$103.8M-62.7%

Longeveron$19.4M-9.1%

By revenue growth

AbbVie+9.5%

Regeneron Pharmaceuticals+5.9%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

AbbVie5.79%-1.5pp

Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on the development of novel cell replacement therapies for serious medical conditions. Utilizing its proprietary AlloSCOPE manufacturing platform, the company creates specialized, fully differentiated allogeneic cells to replace dysfunctional or lost cellular activity in areas such as ophthalmology, neurology, and metabolic diseases. Their 'Replace and Restore' approach aims to provide durable functional recovery through one-time transplant procedures.

Competitive position

A leader in pluripotent cell-based non-oncology development with a proprietary scalable manufacturing platform (AlloSCOPE) and a validated clinical-stage pipeline.

GeographiesUnited States, Israel

Customer segmentsPharmaceutical Companies, Specialized Healthcare Providers

Business modelR&D intensive, Licensing and Royalties, Strategic Collaborations

SuppliersPluripotent cell lines, Third-party raw material suppliers, Gene editing technology providers, Specialized laboratory equipment

CustomersGlobal pharmaceutical companies (e.g., Roche), Clinical trial sites, Specialized surgeons, Patients with degenerative diseases

CountryUnited States of America

Listed1992

Employees75.0

CEOBrian Culley

SectorHealthcare

IndustryBiotechnology

Websitelineagecell.com

FilingsSEC EDGAR

Questions, answered.

What is Lineage Cell Therapeutics's market cap?: Lineage Cell Therapeutics (LCTX) has a market capitalization of $291.7M and trades on AMEX.
Who are Lineage Cell Therapeutics's competitors?: Lineage Cell Therapeutics's key competitors include Regeneron Pharmaceuticals, Inc., AbbVie Inc., Sana Biotechnology, Inc., and others. These companies compete in similar markets and product categories.
Who does Lineage Cell Therapeutics partner with?: Lineage Cell Therapeutics's notable partners include F. Hoffman-La Roche Ltd., Genentech, Inc., William Demant Invest 2 Aps, and others.
What subsidiaries does Lineage Cell Therapeutics have?: Lineage Cell Therapeutics's subsidiaries include Cell Cure Neurosciences Ltd., Asterias Biotherapeutics Incorporated.
Where is Lineage Cell Therapeutics headquartered?: Lineage Cell Therapeutics is headquartered in United States of America and employs approximately 75 people. It has been publicly traded since 1992.